| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by LCR.
Page 3: 1 2 3 4 5 6 7
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 601 | 7 | 10 | 1510 2002 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 47(6):967-968 Boyd AS; King LE; Boyd AS Thalidomide-induced remission of lichen planopilaris | 0 | 0 |
| 602 | 7 | 22 | 1517 2002 LEUKEMIA 16(1):1-6 Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N Thalidomide for the treatment of patients with myelodysplastic syndromes | 15 | 26 |
| 603 | 7 | 8 | 1520 2002 LEUKEMIA & LYMPHOMA 43(2):351-354 Johnston RE; Abdalla SH Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia | 7 | 9 |
| 604 | 7 | 29 | 1523 2002 LEUKEMIA & LYMPHOMA 43(9):1777-1782 Coleman M; Leonard J; Lyons L; Pekle K; Nahum K; Pearse R; Niesvizky R; Michaeli J BLYD (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia | 4 | 6 |
| 605 | 7 | 17 | 1530 2002 MEDICAL ONCOLOGY 19(2):79-86 Merup M; Kutti J; Birgergard G; Mauritzson N; Bjorkholm M; Markevarn B; Malm C; Westin J; Palmblad J; Samuelsson J; Swedish Natl Study Grp Chronic Mye Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia | 4 | 5 |
| 606 | 7 | 31 | 1561 2003 ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH 27(8):2S-6S Enomoto N; Takei Y; Hirose M; Kitamura T; Ikejima K; Sato N Protective effect of thalidomide on endotoxin-induced liver injury | 0 | 1 |
| 607 | 7 | 17 | 1586 2003 APMIS 111:113-116 Chew M; Zhou J; Daugherty A; Eriksson T; Ellermann-Eriksen S; Hansen PR; Falk E Thalidomide inhibits early atherogenesis in apoE-deficient mice | 0 | 0 |
| 608 | 7 | 20 | 1733 2003 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 11(6):785-790 Li XP; Liu XY; Wang J; Wang ZL; Jiang W; Reed E; Zhang Y; Liu YL; Li QQ Effects of thalidomide on the expression of angiogenesis growth factors in human A(549) lung adenocarcinoma cells | 0 | 0 |
| 609 | 7 | 22 | 1740 2003 JOURNAL OF CLINICAL ONCOLOGY 21(1):16-19 Weber D; Rankin K; Gavino M; Delasalle K; Alexanian R Thalidomide alone or with dexamethasone for previously untreated multiple myeloma | 32 | 59 |
| 610 | 7 | 25 | 1744 2003 JOURNAL OF CLINICAL ONCOLOGY 21(14):2732-2739 Lee CK; Barlogie B; Munshi N; Zangari M; Fassas A; Jacobson J; van Rhee F; Cottler-Fox M; Muwalla F; Tricot G DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma | 4 | 11 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 611 | 7 | 26 | 1745 2003 JOURNAL OF CLINICAL ONCOLOGY 21(17):3351-3356 Hwu WJ; Krown SE; Menell JH; Panageas KS; Merrell J; Lamb LA; Williams LJ; Quinn CJ; Foster T; Chapman PB; Livingston PO; Wolchok JD; Houghton AN Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma | 4 | 14 |
| 612 | 7 | 12 | 1748 2003 JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 22(4):129-133 Bernardeschi P; Dentico P; Rossi S; Fiorentini G; Giustarini G; Turano E Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): Results, prognostic factors and side effects in eight patients previously treated with multiple myeloma | 0 | 0 |
| 613 | 7 | 11 | 1815 2003 PRESSE MEDICALE 32(40):1894-1898 Brocvielle H; Muret P; Plenat E; Kantelip JP; Humbert P Management of a patient receiving thalidomide | 0 | 0 |
| 614 | 7 | 20 | 1818 2003 SEMINARS IN HEMATOLOGY 40(4):1-2 Barlogie B Introduction: Thalidomide and the IMiDs in multiple myeloma | 0 | 0 |
| 615 | 7 | 29 | 1824 2003 SEMINARS IN ONCOLOGY 30(2):270-274 Coleman M; Leonard J; Lyons L; Szelenyi H; Niesvizky R Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone | 3 | 6 |
| 616 | 7 | 12 | 1825 2003 SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 16(2):123-129 Hadgraft J; Goosen C; du Plessis J; Flynn G Predicting the dermal absorption of thalidomide and its derivatives | 0 | 0 |
| 617 | 7 | 14 | 1839 2004 ANNALS OF HEMATOLOGY 83(9):588-591 Corso A; Lorenzi A; Terulla V; Airo F; Varettoni M; Mangiacavalli S; Zappasodi P; Rusconi C; Lazzarino M Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone | 0 | 0 |
| 618 | 7 | 8 | 1878 2004 CANCER 100(6):1186-1189 Pro B; Younes A; Albitar M; Dang NH; Samaniego F; Romaguera J; McLaughlin P; Hagemeister FB; Rodriguez MA; Clemons M; Cabanillas F Thalidomide for patients with recurrent lymphoma | 0 | 0 |
| 619 | 7 | 25 | 1908 2004 HAEMATOLOGICA 89(5):552-556 Brenne AT; Romstad LH; Gimsing P; Juliusson G; Turesson I; Romundstad P; Borset M; Sundan A; Waage A Low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma | 0 | 0 |
| 620 | 7 | 34 | 1933 2004 JOURNAL OF PERIODONTOLOGY 75(1):162-168 Lima V; Vidal FDP; Rocha FAC; Brito GAC; Ribeiro RA Effects of tumor necrosis factor-alpha inhibitors pentoxifylline and thalidomide on alveolar bone loss in short-term experimental periodontal disease in rats | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 621 | 7 | 12 | 1950 2004 LEUKEMIA & LYMPHOMA 45(8):1711-1712 Montagut C; Bosch F; Villela L; Rosinol L; Blade J Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide | 0 | 0 |
| 622 | 7 | 10 | 1961 2004 MEDICINA CLINICA 122(15):595-596 Cistero B; Sala M; Soler A; Garcia N Thalidomide in the treatment of recurrent plasmocitomas in an HIV-infected patient | 0 | 0 |
| 623 | 7 | 10 | 1967 2004 NEUROLOGY 62(12):2288-2290 Briani C; Zara G; Rondinone R; Della Libera S; Ermani M; Ruggero S; Ghirardello A; Zampieri S; Doria A Thalidomide neurotoxicity - Prospective study in patients with lupus erythematosus | 1 | 1 |
| 624 | 7 | 10 | 1968 2004 NEUROLOGY 62(12):2291-2293 Cavaletti G; Beronio A; Reni L; Ghiglione E; Schenone A; Briani C; Zara G; Cocito D; Isoardo G; Ciaramitaro P; Plasmati R; Pastorelli F; Frigo M; Piatti M; Carpo M Thalidomide sensory neurotoxicity - A clinical and neurophysiologic study | 1 | 1 |
| 625 | 6 | 13 | 144 1985 BRITISH JOURNAL OF DERMATOLOGY 113:141-144 POWELL RJ; ALLEN BR; JENKINS JS; STEELE L; HUNNEYBALL I; MAURICE PDL; LITTLEWOOD SM INVESTIGATION AND TREATMENT OF OROGENITAL ULCERATION - STUDIES ON A POSSIBLE MODE OF ACTION OF THALIDOMIDE | 7 | 9 |
| 626 | 6 | 30 | 170 1985 REVUE NEUROLOGIQUE 141(11):719-728 CHAPON F; LECHEVALIER B; DASILVA DC; RIVRAIN Y; DUPUY B; DESCHAMPS P THALIDOMIDE INDUCED NEUROPATHY | 5 | 8 |
| 627 | 6 | 15 | 180 1986 BRITISH JOURNAL OF DERMATOLOGY 115(6):677-680 MAURICE PDL; BARKLEY ASJ; ALLEN BR THE EFFECT OF THALIDOMIDE ON ARACHIDONIC-ACID METABOLISM IN HUMAN POLYMORPHONUCLEAR LEUKOCYTES AND PLATELETS | 5 | 5 |
| 628 | 6 | 28 | 187 1986 JOURNAL OF NEUROLOGY 233(2):83-89 HESS CW; HUNZIKER T; KUPFER A; LUDIN HP THALIDOMIDE-INDUCED PERIPHERAL NEUROPATHY - A PROSPECTIVE CLINICAL, NEUROPHYSIOLOGICAL AND PHARMACOGENETIC EVALUATION | 26 | 30 |
| 629 | 6 | 41 | 193 1986 MUSCLE & NERVE 9(9):837-844 LAGUENY A; ROMMEL A; VIGNOLLY B; TAIEB A; VENDEAUDBUSQUET M; DOUTRE MS; JULIEN J THALIDOMIDE NEUROPATHY - AN ELECTROPHYSIOLOGIC STUDY | 21 | 28 |
| 630 | 6 | 11 | 252 1989 BIOCHEMICAL SOCIETY TRANSACTIONS 17(1):114-115 LYNE C; GOWER DB RADIAL THIN-LAYER CHROMATOGRAPHIC AUTORADIOGRAPHIC SCANS OF STEROID-METABOLISM IN THE PRESENCE OF THALIDOMIDE | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 631 | 6 | 33 | 259 1989 JOURNAL OF AUTOIMMUNITY 2(2):197-202 CRAIN E; MCINTOSH KR; GORDON G; PESTRONK A; DRACHMAN DB THE EFFECT OF THALIDOMIDE ON EXPERIMENTAL AUTOIMMUNE MYASTHENIA-GRAVIS | 7 | 9 |
| 632 | 6 | 38 | 293 1990 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 10(4):281-294 HUANG PHT; MCBRIDE WG THALIDOMIDE INDUCED ALTERATION IN SECONDARY STRUCTURE OF RAT EMBRYONIC DNA INVIVO | 6 | 12 |
| 633 | 6 | 9 | 335 1992 NEW ENGLAND JOURNAL OF MEDICINE 327(3):208-209 RYAN J; COLMAN J; PEDERSEN J; BENSON E THALIDOMIDE TO TREAT ESOPHAGEAL ULCER IN AIDS | 24 | 33 |
| 634 | 6 | 10 | 368 1993 MEDICINA CLINICA 100(14):557-557 GARCIAALBEA E; CABRERA F; TEJEIRO J; JIMENEZJIMENEZ FJ MIGRAINE AND THALIDOMIDE | 0 | 0 |
| 635 | 6 | 11 | 384 1994 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 199(2):455-460 NISHIMURA K; HASHIMOTO Y; IWASAKI S ENHANCEMENT OF PHORBOL ESTER-INDUCED PRODUCTION OF TUMOR-NECROSIS-FACTOR-ALPHA BY THALIDOMIDE | 27 | 44 |
| 636 | 6 | 25 | 439 1995 BLOOD 86(9):3604-3609 PARKER PM; CHAO N; NADEMANEE A; ODONNELL MR; SCHMIDT GM; SNYDER DS; STEIN AS; SMITH EP; MOLINA A; STEPAN DE; KASHYAP A; PLANAS I; SPIELBERGER R; SOMLO G; MARGOLIN K; ZWINGENBERGER K; WILSMAN K; NEGRIN RS; LONG GD; NILAND JC; BLUME KG; FORMAN SJ THALIDOMIDE AS SALVAGE THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE | 51 | 85 |
| 637 | 6 | 10 | 448 1995 CLINICAL BIOCHEMISTRY 28(4):467-470 LYON AW; DURAN G; RAISYS VA DETERMINATION OF THALIDOMIDE BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - METHODOLOGICAL STRATEGY FOR CLINICAL-TRIALS | 6 | 7 |
| 638 | 6 | 29 | 460 1995 GENERAL PHARMACOLOGY 26(6):1243-1247 KROGER H; KLEWER M; GRATZ R; DIETRICH A; OCKENFELS H; MIESEL R EXACERBATION OF ACETAMINOPHEN HEPATOTOXICITY BY THALIDOMIDE AND PROTECTION BY NICOTINIC-ACID AMIDE | 1 | 2 |
| 639 | 6 | 40 | 462 1995 HAUTARZT 46(8):553-560 DALLAFIOR S; PUGIN P; CERNY T; BETTICHER D; SAURAT JH; HAUSER C A CASE OF CUTANEOUS LANGERHANS CELL GRANULOMATOSIS SUCCESSFULLY TREATED WITH 2-CHLORODEOXYADENOSINE AND THALIDOMIDE | 4 | 9 |
| 640 | 6 | 14 | 468 1995 JOURNAL OF LIQUID CHROMATOGRAPHY 18(2):297-309 DELON A; FAVRELIERE S; COUET W; COURTOIS PH; BOUQUET S RAPID AND SENSITIVE DETERMINATION OF THALIDOMIDE IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY | 5 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 641 | 6 | 23 | 476 1995 MICROBIAL PATHOGENESIS 19(4):245-255 BURROUGHS MH; TSENOVABERKOVA L; SOKOL K; OSSIG J; TUOMANEN E; KAPLAN G EFFECT OF THALIDOMIDE ON THE INFLAMMATORY RESPONSE IN CEREBROSPINAL-FLUID IN EXPERIMENTAL BACTERIAL-MENINGITIS | 10 | 19 |
| 642 | 6 | 18 | 499 1996 ANTI-CANCER DRUGS 7(3):339-343 Minchinton AI; Fryer KH; Wendt KR; Clow KA; Hayes MMM The effect of thalidomide on experimental tumors and metastases | 29 | 50 |
| 643 | 6 | 11 | 514 1996 BRITISH MEDICAL JOURNAL 313(7054):377-378 Powell RJ New roles for thalidomide | 18 | 24 |
| 644 | 6 | 36 | 518 1996 CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY 81(3):219-223 Klausner JD; Freedman VH; Kaplan G Thalidomide as an anti-TNF-alpha inhibitor: Implications for clinical use | 40 | 57 |
| 645 | 6 | 14 | 534 1996 INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY 111(1):13-17 SantosMendoza T; FavilaCastillo L; Oltra A; Tamariz J; Labarrios F; EstradaParra S; EstradaGarcia I Thalidomide and its metabolites have no effect on human lymphocyte proliferation | 7 | 9 |
| 646 | 6 | 33 | 540 1996 JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 11(3):247-257 Klausner JD; Makonkawkeyoon S; Akarasewi P; Nakata K; Kasinrerk W; Corral L; Dewar RL; Lane HC; Freedman VH; Kaplan G The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M-tuberculosis infection | 51 | 126 |
| 647 | 6 | 21 | 550 1996 MOLECULAR MEDICINE 2(4):506-515 Corral LG; Muller GW; Moreira AL; Chen YX; Wu MD; Stirling D; Kaplan G Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity | 44 | 63 |
| 648 | 6 | 12 | 574 1997 ANALYTICA CHIMICA ACTA 339(1-2):91-97 Simmons BR; Lush RM; Figg WD A reversed-phase high performance liquid chromatography method using solid phase extraction to quantitate thalidomide in human serum | 8 | 10 |
| 649 | 6 | 35 | 582 1997 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 30(10):1199-1207 Moreira AL; Wang J; Sarno EN; Kaplan G Thalidomide protects mice against LPS-induced shock | 11 | 13 |
| 650 | 6 | 22 | 588 1997 CLINICAL AND EXPERIMENTAL IMMUNOLOGY 108(3):428-431 Hauschild A; Kroeger H; Mitchison NA; Ugrinovic S; Zwingenberger K Thalidomide therapy of established collagen-induced arthritis (CIA) not accompanied by an evident Th2 shift | 6 | 12 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 651 | 6 | 16 | 632 1997 LEPROSY REVIEW 68(1):61-66 Powell RJ; GardnerMedwin JMM Guideline for the clinical use and dispensing of thalidomide (Reprinted from the Postgraduate Medical Journal, vol 70, pg 901-904, 1994) | 1 | 3 |
| 652 | 6 | 29 | 642 1997 NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 356(5):529-535 Dunzendorfer S; Schratzberger P; Reinisch N; Kahler CM; Wiedermann CJ Effects of thalidomide on neutrophil respiratory burst, chemotaxis, and transmigration of cytokine-and endotoxin-activated endothelium | 17 | 23 |
| 653 | 6 | 28 | 654 1997 TUBERCLE AND LUNG DISEASE 78(1):47-55 Moreira AL; Tsenova-Berkova L; Wang J; Laochumroonvorapong P; Freeman S; Freedman VH; Kaplan G Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis | 21 | 46 |
| 654 | 6 | 26 | 663 1998 ARCHIV DER PHARMAZIE 331(1):7-12 Teubert U; Zwingenberger K; Wnendt S; Eger K 5 '-substituted thalidomide analogs as modulators of TNF-alpha | 10 | 10 |
| 655 | 6 | 13 | 668 1998 ARTHRITIS AND RHEUMATISM 41(12):2273-2275 Ordi J; Cortes F; Martinez N; Mauri M; De Torres I; Vilardell M Thalidomide induces amenorrhea in patients with lupus disease | 13 | 20 |
| 656 | 6 | 10 | 691 1998 CLINICAL AND EXPERIMENTAL DERMATOLOGY 23(5):233-235 Herranz P; Pizarro A; de Lucas R; Arribas JR; Garcia-Tobaruela A; Pena JM; Casado M Treatment of AIDS-associated prurigo nodularis with thalidomide | 4 | 5 |
| 657 | 6 | 28 | 706 1998 INTERNATIONAL JOURNAL OF STD & AIDS 9(12):751-755 Fife K; Howard MR; Gracie F; Phillips RH; Bower M Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre | 29 | 45 |
| 658 | 6 | 24 | 748 1999 AMERICAN JOURNAL OF PUBLIC HEALTH 89(1):98-101 Annas GJ; Elias S Thalidomide and the Titanic: Reconstructing the technology tragedies of the twentieth century | 5 | 7 |
| 659 | 6 | 12 | 750 1999 ANNALS OF ONCOLOGY 10(7):857-859 Bruera E; Neumann CM; Pituskin E; Calder K; Ball G; Hanson J Thalidomide in patients with cachexia due to terminal cancer: Preliminary report | 15 | 31 |
| 660 | 6 | 11 | 793 1999 CLINICAL NEUROPHYSIOLOGY 110(4):735-739 Sadoh DR; Hawk JLM; Panayiotopoulos CP F-chronodispersion in patients on thalidomide | 5 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 661 | 6 | 10 | 816 1999 INTERNATIONAL JOURNAL OF DERMATOLOGY 38(1):76-77 Pizarro A; Garcia-Tobaruela A; Herranz P; Pinilla J Thalidomide as an inhibitor of tumor necrosis factor-alpha production: a word of caution | 1 | 1 |
| 662 | 6 | 17 | 828 1999 JOURNAL OF INFECTIOUS DISEASES 180(1):61-67 Jacobson JM; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Wu AW; Hooton TM; Sha BE; Shikuma CM; MacPhail LA; Simpson DM; Trapnell CB; Basgoz N; Natl Inst Allergy Infect Dis AIDS Clin Trials G Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection | 27 | 38 |
| 663 | 6 | 15 | 829 1999 JOURNAL OF INFECTIOUS DISEASES 180(1):216-219 Meierhofer C; Dunzendorfer S; Wiederman CJ Protein kinase C-dependent effects on leukocyte migration of thalidomide | 5 | 10 |
| 664 | 6 | 32 | 832 1999 JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS 15(5):429-438 Siefert B; Pleyer U; Muller M; Hartmann C; Keipert S Influence of cyclodextrins on the in vitro corneal permeability and in vivo ocular distribution of thalidomide | 0 | 10 |
| 665 | 6 | 23 | 836 1999 JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN 57(2):92-104 Shimazawa R; Takayama H; Hashimoto Y Development of novel biological response modifiers derived from thalidomide | 0 | 7 |
| 666 | 6 | 24 | 879 2000 AMERICAN JOURNAL OF PATHOLOGY 156(1):151-158 Sauer H; Gunther J; Hescheler J; Wartenberg M Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals | 16 | 33 |
| 667 | 6 | 20 | 890 2000 ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY 126(1):89-92 Dios PD; Sopena B; Cameselle J; Butron M; Crespo M; Ocampo A Thalidomide for the treatment of acquired immunodeficiency syndrome-associated refractory oral ulcers | 2 | 3 |
| 668 | 6 | 16 | 953 2000 CANCER PRACTICE 8(2):101-103 Valorie AM Thalidomide - A new beginning | 0 | 1 |
| 669 | 6 | 34 | 1003 2000 JOURNAL OF CLINICAL ONCOLOGY 18(4):708-715 Fine HA; Figg WD; Jaeckle K; Wen PY; Kyritsis AP; Loeffler JS; Levin VA; Black PM; Kaplan R; Pluda JM; Yung WKA Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas | 78 | 150 |
| 670 | 6 | 16 | 1074 2001 ANNALS OF ONCOLOGY 12(7):987-990 Bertolini F; Mingrone W; Alietti A; Ferrucci PF; Cocorocchio E; Peccatori F; Cineri S; Mancuso P; Corsini C; Burlini A; Zucca E; Martinelli G Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers | 16 | 27 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 671 | 6 | 6 | 1083 2001 ARTHRITIS AND RHEUMATISM 44(10):2456-2457 Lee L; Lawford R; McNeil HP The efficacy of thalidomide in severe refractory seronegative spondylarthropathy: comment on the letter by Breban et al | 2 | 5 |
| 672 | 6 | 12 | 1148 2001 BRITISH JOURNAL OF DERMATOLOGY 144(2):227-228 Allen BR Thalidomide | 4 | 4 |
| 673 | 6 | 6 | 1194 2001 GASTROENTEROLOGY 120(6):1567-1568 Fox MR; Harris A Intractable insomnia after cessation of treatment with thalidomide | 3 | 3 |
| 674 | 6 | 6 | 1236 2001 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 45(6):965-966 George SJ; Hsu S Lichen planopilaris treated with thalidomide | 3 | 6 |
| 675 | 6 | 15 | 1258 2001 OPHTHALMOLOGICA 215(1):70-73 Parentin F; Da Pozzo S; Lepore L; Perissutti P Thalidomide effectiveness for bilateral chronic idiopathic anterior uveitis in a three-year-old child | 2 | 2 |
| 676 | 6 | 48 | 1268 2001 SEMINARS IN HEMATOLOGY 38(3):250-259 Barlogie B; Zangari M; Spencer T; Fassas A; Anaissie E; Badros A; Cromer J; Tricot G Thalidomide in the management of multiple myeloma | 18 | 31 |
| 677 | 6 | 18 | 1272 2001 SEMINARS IN ONCOLOGY 28(6):588-592 Blade J; Esteve J; Rosinol L; Perales M; Montoto S; Tuset M; Montserrat E Thalidomide in refractory and relapsing multiple myeloma | 11 | 13 |
| 678 | 6 | 27 | 1277 2001 SYNTHESIS-STUTTGART (7):999-1000 Seijas JA; Vazquez-Tato MP; Gonzalez-Bande C; Martinez MM; Pacios-Lopez B Microwave promoted synthesis of a rehabilitated drug: Thalidomide | 0 | 2 |
| 679 | 6 | 15 | 1280 2002 ACTA DERMATO-VENEREOLOGICA 82(5):384-386 Kolde G; Schulze P; Sterry W Mixed response to thalidomide therapy in adults: Two cases of multisystem Langerhans' cell histiocytosis | 1 | 2 |
| 680 | 6 | 28 | 1294 2002 ANNALS OF ONCOLOGY 13(7):1029-1035 Escudier B; Lassau N; Couanet D; Angevin E; Mesrati F; Leborgne S; Garofano A; Leboulaire C; Dupouy N; Laplanche A Phase II trial of thalidomide in renal-cell carcinoma | 12 | 23 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 681 | 6 | 7 | 1406 2002 BRITISH JOURNAL OF HAEMATOLOGY 119(3):883-884 Gonzalez-Porras JR; Gonzalez M; Garcia-Sanz R; San Miguel JF Thalidomide in combination with cyclophosphamide and dexamethasone (ThaCyDex) is effective in soft-tissue plasmacytomas | 0 | 0 |
| 682 | 6 | 43 | 1412 2002 CANCER 95(8):1629-1636 Desai AA; Vogelzang NJ; Rini BI; Ansari R; Krauss S; Stadler WM A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma | 8 | 15 |
| 683 | 6 | 6 | 1436 2002 DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT 127(15):818-818 Mensing H New indication for thalidomide? | 0 | 0 |
| 684 | 6 | 38 | 1437 2002 DEVELOPMENTAL DYNAMICS 225(2):186-194 Hansen JM; Gong SG; Philbert M; Harris C Misregulation of gene expression in the redox-sensitive NF-kappa B-dependent limb outgrowth pathway by thalidomide | 1 | 3 |
| 685 | 6 | 20 | 1483 2002 JOURNAL OF CLINICAL ONCOLOGY 20(1):302-306 Motzer RJ; Berg W; Ginsberg M; Russo P; Vuky J; Yu R; Bacik J; Mazumdar M Phase II trial of thalidomide for patients with advanced renal cell carcinoma | 22 | 36 |
| 686 | 6 | 26 | 1488 2002 JOURNAL OF CLINICAL ONCOLOGY 20(11):2610-2615 Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO; Williams LJ; Quinn CJ; Houghton AN Temozolomide plus thalidomide in patients with advanced melanoma: Results of a dose-finding trial | 12 | 22 |
| 687 | 6 | 8 | 1498 2002 JOURNAL OF INVESTIGATIVE DERMATOLOGY 119(5):987-988 Gaspari A Thalidomide neurotoxicity in dermatological patients: The next "STEP'' | 1 | 2 |
| 688 | 6 | 28 | 1502 2002 JOURNAL OF NUCLEAR MEDICINE 43(8):1084-1089 Kinuya S; Kawashima A; Yokoyama K; Koshida K; Konishi S; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts | 1 | 7 |
| 689 | 6 | 24 | 1543 2002 PHARMACEUTICAL RESEARCH 19(1):13-19 Goosen C; Laing TJ; du Plessis J; Goosen TC; Flynn GL Physicochemical characterization and solubility analysis of thalidomide and its N-alkyl analogs | 4 | 4 |
| 690 | 6 | 17 | 1584 2003 ANTICANCER RESEARCH 23(3B):2481-2487 Li XP; Liu XY; Wang J; Wang ZL; Jiang W; Reed E; Zhang Y; Liu YL; Li QQ Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 691 | 6 | 6 | 1667 2003 BONE MARROW TRANSPLANTATION 32(3):343-343 Milone JH; Prates V; Bordone J; Napal J; Garcia C Response to single-agent thalidomide and eligibility to undergo autotransplant for patients with multiple myeloma refractory to VAD | 0 | 0 |
| 692 | 6 | 42 | 1712 2003 DIABETOLOGIA 46(12):1669-1675 Bosco AA; Lerario AC; Santos RF; Wajchenberg BL Effect of thalidomide and rosiglitazone on the prevention of diabetic retinopathy in streptozotocin-induced diabetic rats | 1 | 1 |
| 693 | 6 | 15 | 1728 2003 INTERNAL MEDICINE 42(7):550-551 Dan K Thalidomide as a targeted therapy for multiple myeloma | 0 | 0 |
| 694 | 6 | 40 | 1732 2003 INTERNATIONAL JOURNAL OF HEMATOLOGY 78(5):443-449 Ural AU; Yilmaz MI; Avcu F; Pekel A; Zerman M; Nevruz O; Sengul A; Yalcin A The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide | 0 | 2 |
| 695 | 6 | 15 | 1741 2003 JOURNAL OF CLINICAL ONCOLOGY 21(11):2211-2214 Loprinzi C; Rajkumar SV Why not start with thalidomide? | 0 | 1 |
| 696 | 6 | 10 | 1768 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(3):421-422 Barbui T; Falanga A Thalidomide and thrombosis in multiple myeloma | 2 | 2 |
| 697 | 6 | 10 | 1795 2003 LUPUS 12(9):723-724 Tektonidou MG; Vlachoyiannopoulos PG Antiphospholipid syndrome triggered by thalidomide in a patient with discoid lupus erythematosus | 0 | 0 |
| 698 | 6 | 10 | 1801 2003 NEUROLOGY 60(1):130-132 Gupta A; Cohen BH; Ruggieri P; Packer RJ; Phillips PC Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1 | 1 | 4 |
| 699 | 6 | 25 | 1823 2003 SEMINARS IN ONCOLOGY 30(2):265-269 Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Margaritis D; Matsouka C; Economopoulos T; Anagnostopoulos N Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone | 3 | 5 |
| 700 | 6 | 25 | 1828 2003 WORLD JOURNAL OF SURGERY 27(10):1119-1123 Mall JW; Schwenk W; Philipp AW; Buttemeyer R; Pollmann C Intraperitoneal administration of the angiogenesis inhibitor thalidomide does not impair anastomotic healing following large bowel resection in a rabbit model | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 701 | 6 | 31 | 1855 2004 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 14(16):4141-4145 Noguchi T; Sano H; Shimazawa R; Tanatani A; Miyachi H; Hashimoto Y Phenylhomophthalimide-type NOS inhibitors derived from thalidomide | 0 | 0 |
| 702 | 6 | 23 | 1883 2004 CHEMICAL & PHARMACEUTICAL BULLETIN 52(4):498-499 Shimazawa R; Sano H; Tanatani A; Miyachi H; Hashimoto Y Thalidomide as a nitric oxide synthase inhibitor and its structural development | 1 | 1 |
| 703 | 6 | 21 | 1907 2004 GUT 53(4):609-612 Bauditz J; Schachschal G; Wedel S; Lochs H Thalidomide for treatment of severe intestinal bleeding | 0 | 0 |
| 704 | 6 | 10 | 1911 2004 HAEMATOLOGICA 89(9):1141-1142 Galli M; Elice F; Crippa E; Comotti B; Rodeghiero F; Barbui T Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma | 0 | 0 |
| 705 | 6 | 33 | 1941 2004 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2(2):327-334 Kaushal V; Kaushal GP; Melkaveri SN; Mehta P Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology | 0 | 0 |
| 706 | 5 | 15 | 163 1985 LANCET 2(8446):80-81 [Anon] THALIDOMIDE IN DERMATOLOGY AND LEPROSY | 7 | 0 |
| 707 | 5 | 19 | 176 1986 ARCHIVES OF INTERNAL MEDICINE 146(5):878-881 JORIZZO JL; SCHMALSTIEG FC; SOLOMON AR; CAVALLO T; TAYLOR RS; RUDLOFF HB; SCHMALSTIEG EJ; DANIELS JC THALIDOMIDE EFFECTS IN BEHCETS-SYNDROME AND PUSTULAR VASCULITIS | 25 | 59 |
| 708 | 5 | 19 | 227 1988 BONE MARROW TRANSPLANTATION 3(5):393-398 VOGELSANG GB; HESS AD; SANTOS GW THALIDOMIDE FOR TREATMENT OF GRAFT-VERSUS-HOST DISEASE | 31 | 38 |
| 709 | 5 | 17 | 230 1988 CLINICAL AND EXPERIMENTAL DERMATOLOGY 13(6):408-410 MUNRO CS; COX NH PYODERMA GANGRENOSUM ASSOCIATED WITH BEHCETS SYNDROME - RESPONSE TO THALIDOMIDE | 12 | 19 |
| 710 | 5 | 7 | 329 1992 LANCET 339(8792):549-550 BESSIS D; GUILLOT B; MONPOINT S; DANDURAND M; GUILHOU JJ THALIDOMIDE FOR SYSTEMIC LUPUS-ERYTHEMATOSUS | 27 | 31 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 711 | 5 | 6 | 332 1992 LANCET 339(8805):1362-1362 CARMICHAEL AJ; KNIGHT A THALIDOMIDE - A RESTRICTED ROLE | 3 | 5 |
| 712 | 5 | 32 | 385 1994 BIOGENIC AMINES 10(6):543-554 AUDIT CO THALIDOMIDE-INDUCED POLYAMINE ACYLATION - A NEW INSIGHT INTO THE ACYLATION MECHANISM | 3 | 3 |
| 713 | 5 | 5 | 391 1994 BRITISH MEDICAL JOURNAL 308(6941):1437-1438 CRAWFORD CL SAFETY OF THALIDOMIDE | 4 | 4 |
| 714 | 5 | 34 | 406 1994 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 16(4):717-729 SHANNON EJ; HOWE RC; MCLEAN K; HASTINGS RC THALIDOMIDE DOES NOT PERTURB CD2, CD4, CD5, CD8, HLA-DR, OR HLA-A, HLA-B, HLA-C MOLECULES IN-VITRO ON THE MEMBRANES OF CELLS WITH IMMUNE POTENTIAL | 5 | 5 |
| 715 | 5 | 20 | 428 1994 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 14(3):115-122 HEGER W; SCHMAHL HJ; KLUG S; FELIES A; NAU H; MERKER HJ; NEUBERT D EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES IN THE NONHUMAN PRIMATE CALLITHRIX-JACCHUS .4. TERATOGENICITY OF MU-G/KG DOSES OF THE EM12 ENANTIOMERS | 7 | 15 |
| 716 | 5 | 6 | 446 1995 CLINICAL AND EXPERIMENTAL DERMATOLOGY 20(1):85-85 MISERY L; PEGUETNAVARRO J; THIVOLET J; FAURE M; SCHMITT D; CLAUDY AL THALIDOMIDE DOES NOT AFFECT IN-VITRO MIXED SKIN CELL LYMPHOCYTE REACTIONS | 0 | 1 |
| 717 | 5 | 10 | 451 1995 DIGESTIVE DISEASES AND SCIENCES 40(5):1147-1148 NAUM SM; MOLLOY PJ; KANIA RJ; MCGARR J; VANTHIEL DH USE OF THALIDOMIDE IN TREATMENT AND MAINTENANCE OF IDIOPATHIC ESOPHAGEAL ULCERS IN HIV+ INDIVIDUALS | 7 | 11 |
| 718 | 5 | 5 | 459 1995 GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE 19(1):128-129 SIRE S; FRAISSE P; REY D; JACQUEMIN C; KEMPF G; PARTISANI M; LANG JM EFFECTIVENESS OF THALIDOMIDE IN THE TREATMENT OF ESOPHAGEAL ULCERS IN AIDS | 2 | 2 |
| 719 | 5 | 5 | 479 1995 MOLECULAR MEDICINE TODAY 1(5):210-210 STEWART A IS THALIDOMIDE A MUTAGEN | 0 | 0 |
| 720 | 5 | 38 | 490 1996 AIDS 10(13):1501-1507 ReyesTeran G; SierraMadero JG; delCerro VM; ArroyoFigueroa H; Pasquetti A; Calva JJ; RuizPalacios GM Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial | 49 | 98 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 721 | 5 | 14 | 498 1996 ANNALS OF THE RHEUMATIC DISEASES 55(11):833-836 Huizinga TWJ; Dijkmans BAC; vanderVelde EA; Kraan TCTMV; Verweij CL; Breedveld FC An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis | 20 | 37 |
| 722 | 5 | 21 | 508 1996 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 224(2):426-430 Miyachi H; Azuma A; Hioki E; Iwasaki S; Kobayashi Y; Hashimoto Y Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production | 15 | 25 |
| 723 | 5 | 13 | 519 1996 CLINICAL INFECTIOUS DISEASES 23(3):501-503 Soler RA; Howard M; Brink NS; Gibb D; Tedder RS; Nadal D Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide | 24 | 31 |
| 724 | 5 | 34 | 528 1996 HEPATOLOGY 23(6):1616-1621 LopezTalavera JC; Cadelina G; Olchowski J; Merrill W; Groszmann RJ Thalidomide inhibits tumor necrosis factor alpha decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats | 7 | 52 |
| 725 | 5 | 76 | 544 1996 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 277(3):1649-1658 Arlen RR; Wells PG Inhibition of thalidomide teratogenicity by acetylsalicylic acid: Evidence for prostaglandin H synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate | 9 | 15 |
| 726 | 5 | 25 | 555 1996 NEUROREPORT 7(12):1881-1886 Kanbayashi T; Nishino S; Tafti M; Hishikawa Y; Dement WC; Mignot E Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy | 1 | 6 |
| 727 | 5 | 51 | 561 1996 TERATOLOGY 54(3):126-134 Smith DM; Torres RD; Stephens TD Mesonephros has a role in limb development and is related to thalidomide embryopathy | 0 | 6 |
| 728 | 5 | 5 | 590 1997 CLINICAL CHEMISTRY 43(6):1094-1095 Eriksson T; Bjorkman S Handling of blood samples for determination of thalidomide | 6 | 6 |
| 729 | 5 | 35 | 605 1997 IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY 19(3):313-326 Aseffa A; Dietrich MA; Shannon EJ Effect of thalidomide on apoptosis of lymphocytes and neutrophils | 4 | 5 |
| 730 | 5 | 6 | 633 1997 M S-MEDECINE SCIENCES 13(4):595-596 Audit CO; Aimar C Thalidomide-induced teratogenesis. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 731 | 5 | 32 | 648 1997 RESPIRATORY MEDICINE 91(1):31-39 Tavares JL; Wangoo A; Dilworth P; Marshall B; Kotecha S; Shaw RJ Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages | 24 | 39 |
| 732 | 5 | 19 | 661 1998 ANNALS OF INTERNAL MEDICINE 128(6):494-495 Ehrlich GE Behcet disease and the emergence of thalidomide | 4 | 19 |
| 733 | 5 | 15 | 671 1998 BIOLOGICAL & PHARMACEUTICAL BULLETIN 21(6):638-640 Ishikawa M; Kanno S; Takayanagi M; Takayanagi Y; Sasaki K Thalidomide promotes the release of tumor necrosis factor-alpha (TNF-alpha) and lethality by lipopolysaccharide in mice | 5 | 6 |
| 734 | 5 | 7 | 682 1998 BONE MARROW TRANSPLANTATION 22(9):933-934 Sastry PSRK; Powles RL Thalidomide for chronic GVHD | 0 | 0 |
| 735 | 5 | 14 | 705 1998 INTERNATIONAL JOURNAL OF LEPROSY AND OTHER MYCOBACTERIAL DISEASES 66(1):61-65 Moreira AL; Kaplan G; Villahermosa LG; Fajardo TJ; Abalos RM; Cellona RV; Balagon MVF; Tan EV; Walsh GP Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL | 1 | 9 |
| 736 | 5 | 5 | 725 1998 LANCET 352(9127):544-545 Stambe C; Wicks IP TNF alpha and response of treatment-resistant adult-onset Still's disease to thalidomide | 10 | 25 |
| 737 | 5 | 12 | 811 1999 GUT 45(3):463-464 Ollivier S; Bonnet J; Lemann M; Coffin JC; Modigliani R; Jian R; Bertheau P; Flejou JF Idiopathic giant oesophageal ulcer in an immunocompetent patient. The efficacy of thalidomide treatment | 1 | 2 |
| 738 | 5 | 17 | 814 1999 IMMUNOPHARMACOLOGY 43(1):59-64 Dunzendorfer S; Herold M; Wiedermann CJ Inducer-specific bidirectional regulation of endothelial interleukin-8 production by thalidomide | 8 | 8 |
| 739 | 5 | 11 | 848 1999 NATURE MEDICINE 5(5):489-490 Hales BF Thalidomide on the comeback trail | 30 | 32 |
| 740 | 5 | 11 | 866 1999 SLEEP 22(1):113-115 Kanbayashi T; Shimizu T; Takahashi Y; Kitajima T; Takahashi K; Saito Y; Hishikawa Y Thalidomide increases both REM and stage 3-4 sleep in human adults: A preliminary study | 9 | 11 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 741 | 5 | 5 | 872 2000 AIDS 14(12):1859-1861 Gori A; Rossi MC; Marchetti G; Trabattoni D; Molteni C; Cogliati M; Bandera A; Clerici M; Franzetti F Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease | 5 | 7 |
| 742 | 5 | 15 | 956 2000 CHROMATOGRAPHIA 52(7-8):455-458 Alvarez C; Sanchez-Brunete JA; Torrado-Santiago S; Cadorniga R; Torrado JJ Enantioselective separation of thalidomide on on immobilized alpha(l)-acid glycoprotein chiral stationary phase | 0 | 2 |
| 743 | 5 | 16 | 1020 2000 LIFE SCIENCES 66(2):133-141 Thiel R; Kastner U; Neubert R Expression of adhesion receptors on rat limb bud cells and results of treatment with a thalidomide derivative | 3 | 4 |
| 744 | 5 | 42 | 1053 2000 SEMINARS IN HEMATOLOGY 37(1):35-39 Alexanian R; Anderson KC; Barlogie B; Stirling DI; Thomas DA Thalidomide in hematologic malignancies: Future directions | 5 | 5 |
| 745 | 5 | 13 | 1075 2001 ANNALS OF ONCOLOGY 12(7):991-995 Dimopoulos MA; Zervas K; Kouvatseas G; Galani E; Grigoraki V; Kiamouris C; Vervessou E; Samantas E; Papadimitriou C; Economou O; Gika D; Panayiotidis P; Christakis I; Anagnostopoulos N Thalidomide and dexamethasone combination for refractory multiple myeloma | 30 | 41 |
| 746 | 5 | 14 | 1077 2001 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 45(5):1547-1549 Juffermans NP; Verbon A; Schultz MJ; Hack CE; van Deventer SJH; Speelman P; van der Poll T Thalidomide inhibits granulocyte responses in healthy humans after ex vivo stimulation with bacterial antigens | 2 | 2 |
| 747 | 5 | 12 | 1151 2001 BRITISH JOURNAL OF HAEMATOLOGY 113(2):422-424 Blade J; Perales M; Rosinol L; Tuset M; Montoto S; Esteve O; Cobo F; Villela L; Rafel M; Nomdedeu B; Montserrat E Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas | 18 | 19 |
| 748 | 5 | 21 | 1201 2001 HAEMATOLOGICA 86(4):404-408 Hus M; Dmoszynska A; Soroka-Wojtaszko M; Jawniak D; Legiec W; Ciepnuch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Manko J; Polish Multiple Myeloma Study Grp Thalidomide treatment of resistant or relapsed multiple myeloma patients | 23 | 35 |
| 749 | 5 | 20 | 1206 2001 HAUTARZT 52:962-965 Hoch O; Muller S; Buttner G; Mensing H Thalidomide in the treatment of cutaneous and systemic sarcoidosis | 3 | 5 |
| 750 | 5 | 7 | 1267 2001 SCIENTIST 15(2):1-+ Lewis R The return of thalidomide | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 751 | 5 | 16 | 1289 2002 AMERICAN JOURNAL OF MEDICINE 112(5):412-413 Badros AZ; Siegel E; Bodenner D; Zangari M; Zeldis J; Barlogie B; Tricot G Hypothyroidism in patients with multiple myeloma following treatment with thalidomide | 9 | 10 |
| 752 | 5 | 5 | 1318 2002 BLOOD 99(11):4247-4248 Urbauer E; Kaufmann H; Nosslinger T; Raderer M; Drach J Thromboembolic events during treatment with thalidomide | 13 | 18 |
| 753 | 5 | 5 | 1410 2002 BRITISH MEDICAL JOURNAL 325(7374):1245-1245 Ashby J; Tinwell H Thalidomide is not a human mutagen | 0 | 0 |
| 754 | 5 | 25 | 1444 2002 EUROPEAN JOURNAL OF HEART FAILURE 4(4):455-460 Vescovo G; Ravara B; Angelini A; Sandri M; Carraro U; Ceconi C; Libera LD Effect of thalidomide on the skeletal muscle in experimental heart failure | 1 | 2 |
| 755 | 5 | 24 | 1519 2002 LEUKEMIA & LYMPHOMA 43(1):133-137 Strupp C; Aivado M; Germing U; Gattermann N; Haas R Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: Two case reports | 1 | 4 |
| 756 | 5 | 23 | 1522 2002 LEUKEMIA & LYMPHOMA 43(6):1267-1271 Badros A; Morris C; Zangari M; Barlogie B; Tricot G Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia | 3 | 3 |
| 757 | 5 | 25 | 1548 2002 RADIOLOGE 42(3):222-230 Scherer A; Strupp C; Wittsack HJ; Engelbrecht V; Willers R; Germing U; Gattermann N; Haas R; Modder U Dynamic contrast-enhanced MRI for the evaluation of bone marrow microcirculation in hematologic malignancies before and during thalidomide therapy | 0 | 0 |
| 758 | 5 | 31 | 1551 2002 SEMINARS IN ONCOLOGY 29(6):34-38 Durie BGM Low-dose thalidomide in myeloma: Efficacy and biologic significance | 5 | 8 |
| 759 | 5 | 9 | 1559 2003 ACTA HAEMATOLOGICA 109(3):153-155 Tsiara S; Chaidos A; Kapsali H; Tzouvara E; Bourantas KL Thalidomide administration for the treatment of resistant plasma cell leukemia | 0 | 0 |
| 760 | 5 | 6 | 1572 2003 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 130(4):489-489 Schmutz JL; Barbaud A; Trechot P Thalidomide and thrombosis | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 761 | 5 | 11 | 1673 2003 BRITISH JOURNAL OF DERMATOLOGY 148(5):1060-1061 Tjiu JW; Hsiao CH; Tsai TF Cutaneous Rosai-Dorfman disease: remission with thalidomide treatment | 0 | 0 |
| 762 | 5 | 12 | 1677 2003 BRITISH JOURNAL OF HAEMATOLOGY 121(1):101-103 Steurer M; Sudmeier I; Stauder R; Gastl G Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha | 5 | 7 |
| 763 | 5 | 6 | 1681 2003 BRITISH JOURNAL OF HAEMATOLOGY 122(1):160-161 Harris E; Behrens J; Samson D; Rahemtulla A; Russell NH; Byrne JL Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia | 2 | 3 |
| 764 | 5 | 34 | 1689 2003 CANCER 97(5):1234-1241 Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome | 2 | 7 |
| 765 | 5 | 27 | 1690 2003 CANCER CHEMOTHERAPY AND PHARMACOLOGY 52:S16-S23 Hashimoto Y Structural development of synthetic retinoids and thalidomide-related molecules | 0 | 0 |
| 766 | 5 | 10 | 1714 2003 DRUG METABOLISM AND DISPOSITION 31(8):1072-1072 Zhou SF CYP1A1-mediated activation of thalidomide and suppression of embryo fibroblast proliferation | 0 | 0 |
| 767 | 5 | 10 | 1729 2003 INTERNAL MEDICINE 42(7):605-608 Hayashi T; Yamaguchi I; Saitoh H; Takagi M; Nonaka Y; Nomura T Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis | 1 | 2 |
| 768 | 5 | 41 | 1734 2003 INTERNATIONAL JOURNAL OF ONCOLOGY 22(1):165-173 Yata K; Otsuki T; Kurebayashi J; Uno M; Fujii T; Yawata Y; Takata A; Hyodoh F; Sugihara T Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells | 2 | 3 |
| 769 | 5 | 37 | 1743 2003 JOURNAL OF CLINICAL ONCOLOGY 21(13):2551-2557 Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma | 2 | 7 |
| 770 | 5 | 32 | 1776 2003 LEPROSY REVIEW 74(3):288-290 Pereira GFM On thalidomide and VMO policies | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 771 | 5 | 8 | 1781 2003 LEUKEMIA 17(6):1200-1202 Strupp C; Hildebrandt B; Germing U; Haas R; Gattermann N Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome | 0 | 1 |
| 772 | 5 | 8 | 1782 2003 LEUKEMIA 17(8):1669-1670 Visani G; Mele A; Malagola M; Isidori A; Finelli C; Piccaluga PP Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents | 1 | 1 |
| 773 | 5 | 25 | 1799 2003 MEDICAL ONCOLOGY 20(4):397-401 Fraiman G; Ganti AK; Potti A; Mehdi S Angiosarcoma of the small intestine - Possible role for thalidomide? | 0 | 0 |
| 774 | 5 | 22 | 1831 2004 ACTA NEUROLOGICA SCANDINAVICA 109(3):188-193 Isoardo G; Bergui M; Durelli L; Barbero P; Boccadoro M; Bertola A; Ciaramitaro P; Palumbo A; Bergamasco B; Cocito D Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features | 0 | 0 |
| 775 | 5 | 5 | 1842 2004 ANNALS OF ONCOLOGY 15(3):537-537 Fuente N; Mane JM; Barcelo R; Munoz A; Perez-Hoyos T; Lopez-Vivanco G Tumor lysis syndrome in a multiple myeloma treated with thalidomide | 0 | 0 |
| 776 | 5 | 11 | 1849 2004 ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH 51(3):505-506 Pillemer SR; Leakan RA; Sankar V; Manny J; Baum BJ; Smith J; Chaudhry U; Fox PC; Radfar L; Ligier S; Brennan MT Prominent adverse effects of thalidomide in primary Sjogren's syndrome | 0 | 0 |
| 777 | 5 | 16 | 1856 2004 BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY 70(8):550-551 Kohlhase J; Holmes LB Mutations in SALL4 in malformed father and daughter postulated previously due to reflect mutagenesis by thalidomide | 0 | 0 |
| 778 | 5 | 10 | 1882 2004 CEREBROVASCULAR DISEASES 18(2):175-177 Lenz RA; Saver J Venous sinus thrombosis in a patient taking thalidomide | 0 | 0 |
| 779 | 5 | 17 | 1885 2004 CHIRALITY 16:S36-S39 Nakanishi T; Yamakawa N; Asahi T; Shibata N; Ohtani B; Osaka T Chiral discrimination between thalidomide enantiomers using a solid surface with two-dimensional chirality | 0 | 0 |
| 780 | 5 | 30 | 1913 2004 INTERNATIONAL JOURNAL OF CANCER 110(2):260-265 Kedar I; Mermershtain W; Ivgi H Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 781 | 5 | 26 | 1931 2004 JOURNAL OF NEURO-ONCOLOGY 66(3):295-299 Piribauer M; Czech T; Dieckmann K; Birner P; Hainfellner JA; Prayer D; Fazeny-Dorner B; Weinlander G; Marosi C Stabilization of a progressive hemangioblastoma under treatment with thalidomide | 0 | 0 |
| 782 | 5 | 7 | 1953 2004 LUPUS 13(6):481-482 Pagnoux C; Lutz-Zarrouk V; Michel M; Schaeffer A; Godeau B Cerebral venous thrombosis in a patient with antiphospholipid syndrome treated with thalidomide | 0 | 0 |
| 783 | 5 | 5 | 1960 2004 MEDICAL JOURNAL OF AUSTRALIA 180(7):366-367 Coutsouvelis J; Corallo CE Thalidomide-induced bradycardia and its management | 0 | 0 |
| 784 | 4 | 25 | 64 1983 ARCHIVES OF DERMATOLOGY 119(10):812-815 HASPER MF CHRONIC CUTANEOUS LUPUS-ERYTHEMATOSUS - THALIDOMIDE TREATMENT OF 11 PATIENTS | 21 | 32 |
| 785 | 4 | 38 | 96 1983 SEMAINE DES HOPITAUX 59(45):3101-3104 BELAUBE P; GARCIN G; MARCHAND JP; PRIVAT Y SHOULD THALIDOMIDE BE REHABILITATED | 4 | 7 |
| 786 | 4 | 24 | 109 1984 BIOCHEMICAL PHARMACOLOGY 33(9):1471-1477 BRAUN AG; WEINREB SL TERATOGEN METABOLISM - ACTIVATION OF THALIDOMIDE AND THALIDOMIDE ANALOGS TO PRODUCTS THAT INHIBIT THE ATTACHMENT OF CELLS TO CONCANAVALIN A COATED PLASTIC SURFACES | 15 | 24 |
| 787 | 4 | 18 | 139 1985 ARCHIVOS DE INVESTIGACION MEDICA 16(2):139-143 AVALOSDIAZ E; GUZMANENRIQUEZ L; LOPEZROBLES E; HERRERAESPARZA R INHIBITORY EFFECT OF ENDOCYTOSIS IN POLIMORPHONUCLEAR CELLS CAUSED BY THALIDOMIDE | 0 | 0 |
| 788 | 4 | 30 | 142 1985 BRITISH JOURNAL OF DERMATOLOGY 112(4):475-480 WULFF CH; HOYER H; ASBOEHANSEN G; BRODTHAGEN H DEVELOPMENT OF POLYNEUROPATHY DURING THALIDOMIDE THERAPY | 66 | 85 |
| 789 | 4 | 28 | 186 1986 FOOD AND DRUG LAW JOURNAL 41(4):458-466 SHERMAN M; STRAUSS S THALIDOMIDE - A 25-YEAR PERSPECTIVE | 4 | 14 |
| 790 | 4 | 5 | 226 1988 ARTHRITIS AND RHEUMATISM 31(1):145-146 GUTIERREZRODRIGUEZ O; STARUSTABACAL P; GUTIERREZMONTES O THALIDOMIDE-INDUCED NEUROPATHY IN RHEUMATOID-ARTHRITIS PATIENTS | 2 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 791 | 4 | 11 | 232 1988 FUNDAMENTAL & CLINICAL PHARMACOLOGY 2(6):493-497 DESCOTES J; TEDONE R; EVREUX JC ENHANCEMENT OF ANTIBODY-RESPONSE AND DELAYED-TYPE HYPERSENSITIVITY BY THALIDOMIDE IN MICE | 3 | 3 |
| 792 | 4 | 8 | 249 1988 TRANSPLANTATION PROCEEDINGS 20(2):226-228 VOGELSANG GB; WELLS MC; SANTOS GW; CHEN TL; HESS AD COMBINATION LOW-DOSE THALIDOMIDE AND CYCLOSPORINE PROPHYLAXIS FOR ACUTE GRAFT-VERSUS-HOST DISEASE IN A RAT MISMATCHED MODEL | 14 | 16 |
| 793 | 4 | 15 | 260 1989 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 488(2):417-425 WINCKLER K; KLINKMULLER KD; SCHMAHL HJ DETERMINATION OF THE THALIDOMIDE ANALOGS 2-(2,6-DIOXOPIPERIDINE-3-YL)PHTHALIMIDINE (EM 12), 2-(2,6-DIOXOPIPERIDINE-4-YL)PHTHALIMIDINE (EM 16) AND THEIR METABOLITES IN BIOLOGICAL SAMPLES | 7 | 7 |
| 794 | 4 | 13 | 274 1990 DICP-THE ANNALS OF PHARMACOTHERAPY 24(11):1054-1056 NICOLAU DP; WEST TE THALIDOMIDE - TREATMENT OF SEVERE RECURRENT APHTHOUS STOMATITIS IN PATIENTS WITH AIDS | 9 | 17 |
| 795 | 4 | 14 | 281 1990 JOURNAL OF INTERNAL MEDICINE 228(4):405-407 LARSSON H TREATMENT OF SEVERE COLITIS IN BEHCETS-SYNDROME WITH THALIDOMIDE (CG-217) | 19 | 35 |
| 796 | 4 | 19 | 296 1990 TERATOLOGY 41(2):243-244 KOCH HP PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY | 2 | 4 |
| 797 | 4 | 6 | 319 1992 BRITISH JOURNAL OF DERMATOLOGY 126(1):92-93 MOISSON YF; JANIER M; CIVATTE J THALIDOMIDE FOR RECURRENT ERYTHEMA MULTIFORME | 9 | 12 |
| 798 | 4 | 10 | 325 1992 JOURNAL OF INFECTIOUS DISEASES 166(4):939-940 GEORGHIOU PR; ALLWORTH AM THALIDOMIDE IN PAINFUL AIDS-ASSOCIATED PROCTITIS | 11 | 21 |
| 799 | 4 | 5 | 337 1992 NEW ENGLAND JOURNAL OF MEDICINE 327(10):735-735 CRAWFORD CL THALIDOMIDE NEUROPATHY | 5 | 6 |
| 800 | 4 | 37 | 344 1992 ZEITSCHRIFT FUR NATURFORSCHUNG C-A JOURNAL OF BIOSCIENCES 47(1-2):155-169 KOCHERBECKER U; KOCHER W; OCKENFELS H EMBRYOTOXIC INTERACTIONS BETWEEN A HYDROLYSIS PRODUCT OF THALIDOMIDE AND THE SURFACTANT TWEEN 20 IN MICE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 801 | 4 | 5 | 353 1993 BONE MARROW TRANSPLANTATION 11(3):251-252 LOPEZ J; ULIBARRENA C; GARCIALARANA J; ODRIOZOLA J; DEOTEYZA JP; SASTRE JL; NAVARRO JL THALIDOMIDE AS THERAPY FOR INTESTINAL CHRONIC GVHD | 6 | 9 |
| 802 | 4 | 10 | 383 1994 ARCHIVES OF TOXICOLOGY 68(3):203-205 KLUG S; FELIES A; STURJE H; NOGUEIRA AC; NEUBERT R; FRANKUS E EMBRYOTOXIC EFFECTS OF THALIDOMIDE DERIVATIVES IN THE NONHUMAN PRIMATE CALLITHRIX-JACCHUS .5. LACK OF TERATOGENIC EFFECTS OF PHTHALIMIDOPHTHALIMIDE | 4 | 7 |
| 803 | 4 | 12 | 412 1994 LANCET 343(8895):432-433 JAKEMAN P; SMITH WCS THALIDOMIDE IN LEPROSY REACTION | 8 | 14 |
| 804 | 4 | 13 | 423 1994 POSTGRADUATE MEDICAL JOURNAL 70(830):901-904 POWELL RJ; GARDNERMEDWIN JMM GUIDELINE FOR THE CLINICAL USE AND DISPENSING OF THALIDOMIDE | 39 | 53 |
| 805 | 4 | 22 | 434 1995 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 39(12):2807-2809 PETERSON PK; GEKKER G; BORNEMANN M; CHATTERJEE D; CHAO CC THALIDOMIDE INHIBITS LIPOARABINOMANNAN-INDUCED UP-REGULATION OF HUMAN-IMMUNODEFICIENCY-VIRUS EXPRESSION | 3 | 10 |
| 806 | 4 | 28 | 441 1995 BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH 28(10):1069-1076 AARESTRUP FM; GONCALVESDACOSTA SC; SARNO EN THE EFFECT OF THALIDOMIDE ON BCG-INDUCED GRANULOMAS IN MICE | 2 | 9 |
| 807 | 4 | 25 | 442 1995 BRITISH JOURNAL OF CANCER 72(2):339-343 CHING LM; XU ZF; GUMMER BH; PALMER BD; JOSEPH WR; BAGULEY BC EFFECT OF THALIDOMIDE ON TUMOR-NECROSIS-FACTOR PRODUCTION AND ANTITUMOR-ACTIVITY INDUCED BY 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID | 28 | 44 |
| 808 | 4 | 4 | 443 1995 BRITISH JOURNAL OF DERMATOLOGY 132(1):168-168 MEUNIER L; MARCK Y; RIBEYRE C; MEYNADIER J ADULT CUTANEOUS LANGERHANS CELL HISTIOCYTOSIS - REMISSION WITH THALIDOMIDE TREATMENT | 9 | 20 |
| 809 | 4 | 6 | 449 1995 CLINICAL CHEMISTRY 41(8):1199-1199 HUUPPONEN R; PYYKKO K STABILITY OF THALIDOMIDE IN HUMAN PLASMA | 6 | 8 |
| 810 | 4 | 18 | 470 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 33(2):380-382 MANDERS SM; KOSTMAN JR; MENDEZ L; RUSSIN VL THALIDOMIDE-RESISTANT HIV-ASSOCIATED APHTHAE SUCCESSFULLY TREATED WITH GRANULOCYTE-COLONY-STIMULATING FACTOR | 1 | 7 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 811 | 4 | 18 | 478 1995 MOLECULAR MEDICINE 1(4):384-397 TRAMONTANA JM; UTAIPAT U; MOLLOY A; AKARASEWI P; BURROUGHS M; MAKONKAWKEYOON S; JOHNSON B; KLAUSNER JD; ROM W; KAPLAN G THALIDOMIDE TREATMENT REDUCES TUMOR-NECROSIS-FACTOR-ALPHA PRODUCTION AND ENHANCES WEIGHT-GAIN IN PATIENTS WITH PULMONARY TUBERCULOSIS | 60 | 131 |
| 812 | 4 | 11 | 480 1995 NATURE 375(6531):453-453 ASHBY J; TINWELL H IS THALIDOMIDE MUTAGENIC | 7 | 11 |
| 813 | 4 | 5 | 551 1996 NATURE MEDICINE 2(2):132-132 Crawford CL Thalidomide neuropathy | 1 | 1 |
| 814 | 4 | 11 | 653 1997 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 17(1):R1-R2 Neubert D Never-ending tales of the mode of the teratogenic action of thalidomide | 3 | 5 |
| 815 | 4 | 5 | 664 1998 ARCHIVES OF DERMATOLOGY 134(8):1045-1046 Rousseau L; Beylot-Barry M; Doutre MS; Beylot C Cutaneous sarcoidosis successfully treated with low doses of thalidomide | 12 | 25 |
| 816 | 4 | 13 | 673 1998 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 8(19):2669-2674 Muller GW; Shire MG; Wong LM; Corral LG; Patterson RT; Chen YX; Stirling DI Thalidomide analogs and PDE4 inhibition | 21 | 32 |
| 817 | 4 | 42 | 785 1999 BRITISH JOURNAL OF CANCER 79(1):114-118 Verheul HMW; Panigrahy D; Yuan J; D'Amato RJ Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits | 17 | 33 |
| 818 | 4 | 5 | 791 1999 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 17(3):393-393 de Wazieres B; Gil H; Vuitton DA; Dupond JL Treatment of recurrent oro-genital ulceration with low doses of thalidomide | 2 | 3 |
| 819 | 4 | 10 | 792 1999 CLINICAL INFECTIOUS DISEASES 28(4):892-894 Ramirez-Amador VA; Esquivel-Pedraza L; Ponce-de-Leon S; Reyes-Teran G; Gonzalez-Guevara M; Ponce-de-Leon S; Sierra-Madero JG Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: A double-blind placebo-controlled clinical trial | 4 | 5 |
| 820 | 4 | 24 | 817 1999 INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY 80(1):11-16 Arrieta O; Ortiz-Reyes A; Rembao D; Calvillo M; Rivera E; Sotelo J Protective effect of pentoxifylline plus thalidomide against septic shock in mice | 4 | 8 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 821 | 4 | 52 | 823 1999 JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME 81B(1):9-23 McCredie J; Willert HG Longitudinal limb deficiencies and the sclerotomes - An analysis of 378 dysmelic malformations induced by thalidomide | 0 | 8 |
| 822 | 4 | 5 | 837 1999 LANCET 353(9149):324-324 Klausner JD; Kaplan G; Haslett PAJ Thalidomide in toxic epidermal necrolysis | 7 | 8 |
| 823 | 4 | 11 | 846 1999 NATURE 400(6743):419-420 Neubert R; Merker HT; Neubert D Developmental model for thalidomide action | 3 | 4 |
| 824 | 4 | 4 | 888 2000 ARCHIVES OF DERMATOLOGY 136(12):1442-1443 Camisa C; Popovsky JL Effective treatment of oral erosive lichen planus with thalidomide | 6 | 11 |
| 825 | 4 | 8 | 941 2000 BLOOD 96(12):3995-3996 Koc S; Leisenring W; Flowers MED; Anasetti C; Deeg HJ; Nash RA; Sanders JE; Witherspoon RP; Appelbaum FR; Storb R; Martin PJ Thalidomide for treatment of patients with chronic graft-versus-host disease | 14 | 23 |
| 826 | 4 | 4 | 949 2000 BRITISH JOURNAL OF HAEMATOLOGY 110(3):754-754 Gutheil J; Finucane D Thalidomide therapy in refractory solid tumour patients | 10 | 13 |
| 827 | 4 | 8 | 982 2000 GASTROENTEROLOGY 119(2):596-596 Fishman SJ; Feins NR; D'Amato RJ; Folkman J Thalidomide therapy for Crohn's disease | 5 | 12 |
| 828 | 4 | 9 | 985 2000 HAEMATOLOGICA 85(10):1111-1112 Pini M; Baraldi A; Pietrasanta D; Allione B; Depaoli L; Salvi F; Levis A Low-dose thalidomide in the treatment of refractory myeloma | 11 | 19 |
| 829 | 4 | 17 | 1000 2000 JOURNAL OF CHILD NEUROLOGY 15(8):497-503 Schoeman JF; Springer P; Ravenscroft A; Donald PR; Bekker LG; van Rensburg AJ; Hanekom WA; Haslett PAJ; Kaplan G Adjunctive thalidomide therapy of childhood tuberculous meningitis: Possible anti-inflammatory role | 8 | 11 |
| 830 | 4 | 5 | 1011 2000 JOURNAL OF INFECTIOUS DISEASES 182(2):640-640 Kaplan G Tumor necrosis factor-alpha increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus coinfection - Reply | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 831 | 4 | 10 | 1024 2000 MEDICINA-BUENOS AIRES 60:61-65 Politi PM Thalidomide. Clinical trials in cancer. | 1 | 1 |
| 832 | 4 | 5 | 1027 2000 MUSCLE & NERVE 23(8):1301-1302 Rao DG; Kane NM; Oware A Thalidomide neuropathy: Role of F-wave monitoring | 5 | 5 |
| 833 | 4 | 6 | 1033 2000 NEW ENGLAND JOURNAL OF MEDICINE 343(13):972-973 Rajkumar SV; Gertz MA; Witzig TE Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. | 23 | 33 |
| 834 | 4 | 12 | 1039 2000 ONCOLOGY-NEW YORK 14(12):17-20 Eisen TG Thalidomide in solid tumors: The London experience | 11 | 15 |
| 835 | 4 | 7 | 1065 2001 AMERICAN JOURNAL OF GASTROENTEROLOGY 96(4):1305-1306 Ginsburg PM; Hanan I; Ehrenpreis ED Treatment of severe esophageal Crohn's disease with thalidomide | 8 | 10 |
| 836 | 4 | 18 | 1088 2001 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 7(5):265-273 Arora M; Wagner JE; Davies SM; Blazar BR; Defor T; Enright H; Miller WF; Weisdorf DJ Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease | 8 | 15 |
| 837 | 4 | 4 | 1144 2001 BONE MARROW TRANSPLANTATION 27(2):229-230 Schlossberg H; Klumpp T; Sabol P; Herman J; Mangan K Severe cutaneous ulceration following treatment with thalidomide for GVHD | 0 | 1 |
| 838 | 4 | 4 | 1150 2001 BRITISH JOURNAL OF DERMATOLOGY 144(6):1292-1293 Passeron T; Lacour JP; Murr D; Ortonne JP Thalidomide-induced amenorrhoea: two cases | 4 | 4 |
| 839 | 4 | 17 | 1170 2001 CLINICAL CANCER RESEARCH 7(7):1888-1893 Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Kruger EA; Gubish E; Pluda JM; Reed E A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer | 25 | 60 |
| 840 | 4 | 10 | 1228 2001 JOURNAL OF INFECTIOUS DISEASES 183(2):343-346 Jacobson JM; Greenspan JS; Spritzler J; Fox L; Fahey JL; Jackson JB; Chernoff M; Wohl DA; Pulvirenti JJ; Hooton TM; Shikuma C; Natl Inst Allergy Infect Dis AIDS Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers | 1 | 3 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 841 | 4 | 29 | 1232 2001 JOURNAL OF NEURO-ONCOLOGY 55(1):11-17 Mawrin C; Aumann V; Kirches E; Schneider-Stock R; Scherlach C; Vogel S; Mittler U; Dietzmann K; Krause G; Weis S Gliomatosis cerebri: Post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide | 0 | 4 |
| 842 | 4 | 8 | 1255 2001 ONCOLOGY-NEW YORK 15(7):877-878 Govindarajan R Current status of thalidomide in the treatment of cancer - The Rajkumar article reviewed | 0 | 0 |
| 843 | 4 | 6 | 1296 2002 ANNALS OF ONCOLOGY 13(10):1636-1640 Grover JK; Uppal G; Raina V The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma | 3 | 4 |
| 844 | 4 | 4 | 1319 2002 BLOOD 99(11):4248-4248 Lee FC Second response to lower-dose thalidomide in a patient with multiple myeloma | 2 | 2 |
| 845 | 4 | 23 | 1322 2002 BLOOD 100(4):1168-1171 Zangari M; Siegel E; Barlogie B; Anaissie E; Saghafifar F; Fassas A; Morris C; Fink L; Tricot G Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy | 19 | 33 |
| 846 | 4 | 6 | 1399 2002 BRITISH JOURNAL OF DERMATOLOGY 146(6):1112-1113 Pouaha J; Martin S; Reichert-Penetrat S; Trechot P; Barbaud A; Schmutz JL Thalidomide and sexual dysfunction in men | 0 | 0 |
| 847 | 4 | 5 | 1401 2002 BRITISH JOURNAL OF HAEMATOLOGY 117(4):996-997 Bauduer F Efficacy of thalidomide in the treatment of VAD-refractory plasma cell leukaemia appearing after autologous stem cell transplantation for multiple myeloma | 0 | 0 |
| 848 | 4 | 4 | 1402 2002 BRITISH JOURNAL OF HAEMATOLOGY 118(1):347-347 Myers B; Dolan G Analysis of durability of response to thalidomide treatment for relapsed myeloma patients | 1 | 1 |
| 849 | 4 | 5 | 1417 2002 CELL SIGNALING, TRANSCRIPTION, AND TRANSLATION AS THERAPEUTIC TARGETS 973:414-418 Jin SH; Il Kim T; Han DS; Shin SK; Kim WH Thalidomide suppresses the interleukin 1 beta-induced NF kappa B signaling pathway in colon cancer cells | 1 | 3 |
| 850 | 4 | 7 | 1460 2002 HAEMATOLOGICA 87(3):327-328 Corso A; Lorenzi A; Orlandi E; Astori C; Mangiacavalli S; Lazzarino M Advantages of using thalidomide for the management of patients with refractory myeloma | 3 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 851 | 4 | 40 | 1477 2002 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 8(5):256-259 Barthel HR; Charrier U; Kramer M; Loch C Successful treatment of idiopathic febrile panniculitis (Weber-Christian disease) with thalidomide in a patient having failed multiple other medical therapies | 0 | 0 |
| 852 | 4 | 4 | 1485 2002 JOURNAL OF CLINICAL ONCOLOGY 20(5):1429-1430 Nathan PD; Gore ME; Eisen TG Unexpected toxicity of combination thalidomide and interferon alfa-2a treatment in metastatic renal cell carcinoma | 8 | 12 |
| 853 | 4 | 5 | 1486 2002 JOURNAL OF CLINICAL ONCOLOGY 20(8):2212-2212 Cany L; Fitoussi O; Boiron JM; Marit G Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma | 4 | 4 |
| 854 | 4 | 40 | 1505 2002 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 27(3-4):497-505 Trapp O; Schoetz G; Schurig V Stereointegrity of thalidomide: gas-chromatographic determination of the enantiomerization barrier | 0 | 2 |
| 855 | 4 | 26 | 1521 2002 LEUKEMIA & LYMPHOMA 43(2):401-406 Dmoszynska A; Bojarska-Junak A; Domanski D; Rolinski J; Hus M; Soroka-Wojtaszko M Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma | 2 | 6 |
| 856 | 4 | 38 | 1532 2002 MICROBES AND INFECTION 4(11):1193-1202 Teo SK; Resztak KE; Scheffler MA; Kook KA; Zeldis JB; Stirling DI; Thomas SD Thalidomide in the treatment of leprosy | 8 | 10 |
| 857 | 4 | 11 | 1535 2002 OBSTETRICS AND GYNECOLOGY 99(1):125-128 Ances BM New concerns about thalidomide | 1 | 3 |
| 858 | 4 | 17 | 1539 2002 ONCOLOGY-NEW YORK 16(4):23-26 Govindarajan R Irinoteean/Thalidomide in metastatic colorectal cancer | 5 | 6 |
| 859 | 4 | 19 | 1573 2003 ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 130(12):1109-1112 Macario-Barrel A; Balguerie X; Joly P Treatment of erosive oral lichen planus with thalidomide | 0 | 0 |
| 860 | 4 | 9 | 1672 2003 BRITISH JOURNAL OF DERMATOLOGY 148(3):601-602 Worm M; Kolde G Schnitzler's syndrome: successful treatment of two patients using thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 861 | 4 | 12 | 1679 2003 BRITISH JOURNAL OF HAEMATOLOGY 121(5):768-771 Anagnostopoulos A; Weber D; Rankin K; Delasalle K; Alexanian R Thalidomide and dexamethasone for resistant multiple myeloma | 11 | 16 |
| 862 | 4 | 7 | 1680 2003 BRITISH JOURNAL OF HAEMATOLOGY 122(1):159-160 Santos AB; Llamas P; Roman A; Prieto E; de Ona R; de Velasco JF; Tomas JF Evaluation of thrombophylic states in myeloma patients receiving thalidomide: A reasonable doubt | 2 | 2 |
| 863 | 4 | 10 | 1683 2003 BRITISH JOURNAL OF HAEMATOLOGY 123(2):305-308 Thompson MA; Witzig TE; Kumar S; Timm MM; Haug J; Fonseca R; Greipp PR; Lust JA; Rajkumar SV Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma | 2 | 4 |
| 864 | 4 | 39 | 1694 2003 CELLULAR AND MOLECULAR BIOLOGY 49(7):1117-1124 Ezell TN; Maloney N; Githua JW; Taylor LD Exposure to the anti-TNF-alpha drug thalidomide induces apoptotic cell death in human T leukemic cells | 0 | 0 |
| 865 | 4 | 12 | 1697 2003 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 21(2):272-272 Meaux-Ruault N; Magy N; Gil H; Dupond JL Efficacy of thalidomide in refractory adult Still's disease: A new case report | 0 | 0 |
| 866 | 4 | 20 | 1704 2003 CLINICAL LYMPHOMA 4(1):32-35 Zangari M; Barlogie B; Thertulien R; Jacobson J; Eddleman P; Fink L; Fassas A; Van Rhee F; Talamo G; Lee CK; Tricot G Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival | 3 | 6 |
| 867 | 4 | 10 | 1726 2003 HAEMATOLOGICA 88(8):958-960 Corso A; Lorenzi A; Zapposodi P; Invernizzi R; Vanelli L; Lazzarino M Early changes in bone marrow morphology induced by thalidomide in patients with refractory myeloma | 0 | 0 |
| 868 | 4 | 10 | 1727 2003 HAEMATOLOGICA 88(12):1432-1433 Offidani M; Marconi M; Corvotta L; Olivieri A; Catarini M; Leoni P Thalidomide plus oral melphalan for advanced multiple myeloma: a phase II study | 0 | 1 |
| 869 | 4 | 9 | 1737 2003 JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 9(2):96-98 Ching DWT; McClintock A; Beswick F Successful treatment with low-dose thalidomide in a patient with both Behcet's disease and complex regional pain syndrome type I - Case report | 0 | 0 |
| 870 | 4 | 37 | 1742 2003 JOURNAL OF CLINICAL ONCOLOGY 21(12):2299-2304 Fine HA; Wen PY; Maher EA; Viscosi E; Batchelor T; Lakhani N; Figg WD; Purow BW; Borkowf CB Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas | 2 | 5 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 871 | 4 | 4 | 1757 2003 JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 37(4):522-522 Ahmed M; El-Hadi S; Jenkins HR Thalidomide in Crohn disease and the risk of peripheral neuropathy | 0 | 0 |
| 872 | 4 | 19 | 1827 2003 SYNTHETIC COMMUNICATIONS 33(8):1375-1382 Chang MY; Chen ST; Chang NC A synthesis of racemic thalidomide | 0 | 4 |
| 873 | 4 | 5 | 1871 2004 BRITISH JOURNAL OF HAEMATOLOGY 125(1):96-97 Fakhouri F; Guerraoui H; Presne C; Peltier J; Delarue R; Muret P; Knebelmann B Thalidomide in patients with multiple myeloma and renal failure | 0 | 0 |
| 874 | 4 | 22 | 1899 2004 EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 21(4):465-469 Abraham MH Hydrogen bond and other descriptors for thalidomide and its N-alkyl analogs; prediction of physicochemical and biological properties | 0 | 0 |
| 875 | 4 | 13 | 1948 2004 LEUKEMIA & LYMPHOMA 45(1):179-181 Baird R; van Zyl-Smit RN; Iveson A; Duddy J; Rassam S Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia | 0 | 0 |
| 876 | 3 | 34 | 82 1983 DEVELOPMENT GROWTH & DIFFERENTIATION 25(4):361-373 MCBRIDE WG; VARDY PH PATHOGENESIS OF THALIDOMIDE TERATOGENESIS IN THE MARMOSET (CALLITHRIX-JACCHUS) - EVIDENCE SUGGESTING A POSSIBLE TROPHIC INFLUENCE OF CHOLINERGIC NERVES IN LIMB MORPHOGENESIS | 1 | 6 |
| 877 | 3 | 35 | 107 1984 ARCHIVES OF DERMATOLOGY 120(11):1466-1470 ARONSON IK; YU R; WEST DP; VANDENBROEK H; ANTEL J THALIDOMIDE-INDUCED PERIPHERAL NEUROPATHY - EFFECT OF SERUM FACTOR ON NERVE CULTURES | 35 | 39 |
| 878 | 3 | 18 | 156 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 12(1):85-90 GRINSPAN D SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT | 25 | 42 |
| 879 | 3 | 13 | 166 1985 LEPROSY REVIEW 56(4):297-301 SHANNON EJ; TRUMAN RW; CHRISTY SA; BROWN LM; VADIEE R; HASTINGS RC EFFECT OF THALIDOMIDE ON INDUCTION OF ANTIBODY-SYNTHESIS IN MICE TO THE T-INDEPENDENT ANTIGEN, DNP-FICOLL | 5 | 6 |
| 880 | 3 | 12 | 171 1985 TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS 5(3):149-158 BRAUN AG; WEINREB SL TERATOGEN METABOLISM - SPONTANEOUS DECAY PRODUCTS OF THALIDOMIDE AND THALIDOMIDE ANALOGS ARE NOT BIOACTIVATED BY LIVER-MICROSOMES | 11 | 15 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 881 | 3 | 14 | 174 1986 ACTA PATHOLOGICA MICROBIOLOGICA ET IMMUNOLOGICA SCANDINAVICA SECTION C-IMMUNOLOGY 94(6):233-237 NIELSEN H; VALERIUS NH THALIDOMIDE ENHANCES SUPEROXIDE ANION RELEASE FROM HUMAN POLYMORPHONUCLEAR AND MONONUCLEAR LEUKOCYTES | 4 | 7 |
| 882 | 3 | 10 | 188 1986 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 14(2):282-283 ARONSON IK; WEBER L; WEST D; BUYS C; REDER A; ANTEL J THALIDOMIDE AND LYMPHOCYTE FUNCTION | 6 | 6 |
| 883 | 3 | 32 | 205 1987 ARCHIVES OF TOXICOLOGY 60(5):376-381 STERZ H; NOTHDURFT H; LEXA P; OCKENFELS H TERATOLOGIC STUDIES ON THE HIMALAYAN RABBIT - NEW ASPECTS OF THALIDOMIDE-INDUCED TERATOGENESIS | 6 | 10 |
| 884 | 3 | 4 | 234 1988 LANCET 1(8577):117-117 LIM SH; MCWHANNELL A; VORA AJ; BOUGHTON BJ SUCCESSFUL TREATMENT WITH THALIDOMIDE OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER BONE-MARROW TRANSPLANTATION | 32 | 35 |
| 885 | 3 | 5 | 235 1988 LANCET 1(8581):359-359 SAURAT JH; CAMENZIND M; HELG C; CHAPUIS B THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE AFTER BONE-MARROW TRANSPLANTATION | 26 | 31 |
| 886 | 3 | 3 | 239 1988 LANCET 2(8623):1317-1317 HENEY D; LEWIS IJ; BAILEY CC THALIDOMIDE FOR CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDREN | 9 | 14 |
| 887 | 3 | 219 | 248 1988 TERATOLOGY 38(3):241-251 BRENT RL; HOLMES LB CLINICAL AND BASIC SCIENCE LESSONS FROM THE THALIDOMIDE TRAGEDY - WHAT HAVE WE LEARNED ABOUT THE CAUSES OF LIMB DEFECTS | 7 | 37 |
| 888 | 3 | 6 | 254 1989 BONE MARROW TRANSPLANTATION 4(5):598-598 HEATON DC FAILURE OF THALIDOMIDE TO CONTROL BRONCHIOLITIS OBLITERANS POST BONE-MARROW TRANSPLANT | 1 | 3 |
| 889 | 3 | 5 | 256 1989 BRITISH MEDICAL JOURNAL 298(6671):432-432 YOULE M; CLARBOUR J; FARTHING C; CONNOLLY M; HAWKINS D; STAUGHTON R; GAZZARD B TREATMENT OF RESISTANT APHTHOUS ULCERATION WITH THALIDOMIDE IN PATIENTS POSITIVE FOR HIV ANTIBODY | 56 | 103 |
| 890 | 3 | 15 | 265 1989 TOXICOLOGY LETTERS 45(1):23-33 SCHMAHL HJ; HEGER W; NAU H THE ENANTIOMERS OF THE TERATOGENIC THALIDOMIDE ANALOG EM-12 .2. CHEMICAL-STABILITY, STEREOSELECTIVITY OF METABOLISM AND RENAL EXCRETION IN THE MARMOSET MONKEY | 7 | 17 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 891 | 3 | 13 | 284 1990 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 23(5):941-944 RUSTIN MHA; GILKES JJH; ROBINSON TWE PYODERMA-GANGRENOSUM ASSOCIATED WITH BEHCETS-DISEASE - TREATMENT WITH THALIDOMIDE | 14 | 27 |
| 892 | 3 | 3 | 285 1990 LANCET 335(8701):1343-1343 GORIN I; VILETTE B; GEHANNO P; ESCANDE JP THALIDOMIDE IN HYPERALGIC PHARYNGEAL ULCERATION OF AIDS | 21 | 31 |
| 893 | 3 | 12 | 295 1990 TERATOLOGY 41(2):241-242 STEPHENS TD PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY | 0 | 0 |
| 894 | 3 | 10 | 297 1990 TERATOLOGY 41(2):245-246 STEPHENS TD PROPOSED MECHANISMS OF ACTION IN THALIDOMIDE EMBRYOPATHY | 1 | 3 |
| 895 | 3 | 10 | 303 1991 BRITISH MEDICAL JOURNAL 303(6800):470-470 WATERS MFR USE OF THALIDOMIDE IN LEPROSY | 5 | 5 |
| 896 | 3 | 10 | 304 1991 BRITISH MEDICAL JOURNAL 303(6809):1062-1063 CRAWFORD CL USE OF THALIDOMIDE IN LEPROSY | 0 | 0 |
| 897 | 3 | 4 | 321 1992 GENITOURINARY MEDICINE 68(6):424-425 STRAZZI S; LEBBE C; GEOFFRAY C; ABLON G; MOREL P; VEROLA O; MOLINA JM APHTHOUS ULCERS IN HIV-INFECTED PATIENTS - TREATMENT WITH THALIDOMIDE | 8 | 10 |
| 898 | 3 | 9 | 324 1992 JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS 582(1-2):211-216 ERIKSSON T; BJORKMAN S; FYGE A; EKBERG H DETERMINATION OF THALIDOMIDE IN PLASMA AND BLOOD BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - AVOIDING HYDROLYTIC DEGRADATION | 44 | 44 |
| 899 | 3 | 18 | 326 1992 JOURNAL OF MEDICAL GENETICS 29(10):716-723 SMITHELLS RW; NEWMAN CGH RECOGNITION OF THALIDOMIDE DEFECTS | 9 | 25 |
| 900 | 3 | 6 | 340 1992 TRANSPLANTATION PROCEEDINGS 24(6):2560-2561 ERIKSSON T; RIESBECK K; OSTRAAT O; EKBERG H; BJORKMAN S DRUG EXPOSURE AND FLOW-CYTOMETRY ANALYSES IN A THALIDOMIDE TREATMENT SCHEDULE THAT PROLONGS RAT CARDIAC GRAFT-SURVIVAL | 6 | 7 |